No association between decreases in serum immunoglobulin (Ig) levels below lower limit of normal (LLN) and serious infections (SI) with long term ublituximab (UBL) treatment in patients with Relapsing Multiple Sclerosis (RMS)

Drug Category: Array
Conference Category: Array
Lead Author: Cree B, et al.
Published Date: 29/05/2025
Download Link: /wp-content/uploads/2025/09/CMSC-2025-5-year-Ig-LLN-and-SI_final-Steinman-Cree.pdf
Download Text:
Popup Confirmation?:
site-sidebar-layout: default
ast-site-content-layout: default
site-content-style: default
site-sidebar-style: default
theme-transparent-header-meta: default
stick-header-meta: default
astra-migrate-meta-layouts: set
Scroll to Top